Spero Therapeutics Inc Net Assets
Spero Therapeutics Inc net assets. Based on the latest financial reports, Spero Therapeutics Inc (SPRO) has net assets worth $59.02 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($68.92 Million) and total liabilities ($9.90 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of Spero Therapeutics Inc to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $59.02 Million |
| % of Total Assets | 85.64% |
| Annual Growth Rate | N/A |
| 5-Year Change | -33.15% |
| 10-Year Change | 827.86% |
| Growth Volatility | 388.83 |
Net Assets of Spero Therapeutics Inc (2015–2025)
Net assets of Spero Therapeutics Inc from 2015 to 2025. This chart illustrates how Spero Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See SPRO net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Spero Therapeutics Inc (2015–2025)
The table below shows the annual net assets of Spero Therapeutics Inc from 2015 to 2025. For live market cap and overall valuation, see how much is Spero Therapeutics Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $59.02 Million | +27.96% |
| 2024-12-31 | $46.12 Million | -56.85% |
| 2023-12-31 | $106.89 Million | +40.77% |
| 2022-12-31 | $75.93 Million | -13.99% |
| 2021-12-31 | $88.29 Million | -33.13% |
| 2020-12-31 | $132.04 Million | +77.06% |
| 2019-12-31 | $74.57 Million | -35.63% |
| 2018-12-31 | $115.86 Million | +36.37% |
| 2017-12-31 | $84.96 Million | +1235.59% |
| 2016-12-31 | $6.36 Million | +2575.10% |
| 2015-12-31 | $-257.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Spero Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 43296600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Spero Therapeutics Inc Net Assets Breakdown (December 2025)
Spero Therapeutics Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $56.00K | 0.09% |
| Other Components | $510.03 Million | 864.15% |
| Total Equity | $59.02 Million | 100.00% |
Spero Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Spero Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Professional Computer Technology Ltd
TWO:6270
|
$60.23 Million |
|
Sports Entertainment Group Ltd
AU:SEG
|
$60.27 Million |
|
Orbitech Co. Ltd
KQ:046120
|
$60.28 Million |
|
Alliance Witan Ord
LSE:ALW
|
$60.28 Million |
|
James Bay Minerals Ltd
AU:JBY
|
$60.21 Million |
|
Deniz Gayrimenkul Yatirim Ortakligi AS
IS:DZGYO
|
$60.20 Million |
|
Kleannara Co Ltd
KO:004545
|
$60.19 Million |
|
GFL Limited
NSE:GFLLIMITED
|
$60.16 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Spero Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 46,123,000 to 59,021,000, a change of 12,898,000 (28.0%).
- Net income of 8,572,000 contributed positively to equity growth.
- Other factors increased equity by 4,326,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $8.57 Million | +14.52% |
| Other Changes | $4.33 Million | +7.33% |
| Total Change | $- | 27.96% |
Book Value vs Market Value Analysis
This analysis compares Spero Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.04x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 35.05x to 1.04x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.03 | $1.04 | x |
| 2016-12-31 | $1.54 | $1.04 | x |
| 2017-12-31 | $32.84 | $1.04 | x |
| 2018-12-31 | $7.24 | $1.04 | x |
| 2019-12-31 | $4.11 | $1.04 | x |
| 2020-12-31 | $5.90 | $1.04 | x |
| 2021-12-31 | $2.86 | $1.04 | x |
| 2022-12-31 | $2.02 | $1.04 | x |
| 2023-12-31 | $2.02 | $1.04 | x |
| 2024-12-31 | $0.85 | $1.04 | x |
| 2025-12-31 | $1.00 | $1.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Spero Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.52%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.38%
- • Asset Turnover: 0.87x
- • Equity Multiplier: 1.17x
- Recent ROE (14.52%) is above the historical average (-539.68%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -5180.61% | 0.00% | 0.00x | 36.61x | $-10.17 Million |
| 2016 | -250.67% | -7609.25% | 0.02x | 1.35x | $-26.51 Million |
| 2017 | -54.26% | -2329.31% | 0.02x | 1.10x | $-54.59 Million |
| 2018 | -35.96% | -1050.48% | 0.03x | 1.11x | $-53.25 Million |
| 2019 | -80.69% | -1268.98% | 0.04x | 1.42x | $-67.63 Million |
| 2020 | -58.71% | -830.86% | 0.06x | 1.16x | $-90.72 Million |
| 2021 | -101.66% | -2923.65% | 0.02x | 1.94x | $-98.58 Million |
| 2022 | -61.13% | -95.55% | 0.39x | 1.64x | $-54.01 Million |
| 2023 | 21.34% | 21.98% | 0.57x | 1.71x | $12.12 Million |
| 2024 | -148.66% | -142.91% | 0.43x | 2.40x | $-73.18 Million |
| 2025 | 14.52% | 14.38% | 0.87x | 1.17x | $2.67 Million |
Industry Comparison
This section compares Spero Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Spero Therapeutics Inc (SPRO) | $59.02 Million | -5180.61% | 0.17x | $60.22 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including … Read more